Paper Details

  1. Home
  2. Paper Details

Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial.

Author: CorluyLuk, De BrabanterGriet, De CockDiederik, DurnezAnne, GeensElke, GeusensPiet, JolyJohan, JoosRik, LangenakenChristine, LenaertsJan, MeyfroidtSabrina, RaemanFrank, RavelingienIsabelle, RemansJan, SileghemAn, TaelmanVeerle, Van EsscheEls, Van der ElstKristien, Vander CruyssenBert, VandevyvereKlaas, VanhoofJohan, VerschuerenPatrick, WesthovensRene

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Pragmatic Clinical TrialA trial conducted in a real-world clinical setting. It evaluates the effectiveness of interventions in everyday healthcare environments.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study examined different ways to combine disease-modifying antirheumatic drugs (DMARDs) with glucocorticoids (GCs) for treating early rheumatoid arthritis (ERA). The study looked at different combinations of DMARDs and strategies for using GCs to induce remission in patients with a poor prognosis. The study also examined the use of methotrexate (MTX) with or without GCs to induce remission in patients with a good prognosis. The study focused on the first year of treatment.
Paper Details　
Original Abstract of the Article :
Combining disease-modifying antirheumatic drugs (DMARDs) with glucocorticoids (GCs) is an effective treatment strategy for early rheumatoid arthritis (ERA), yet the ideal schedule and feasibility in daily practice are debated. We evaluated different DMARD combinations and GC remission induction sche...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1136/annrheumdis-2016-209212

データ提供：米国国立医学図書館（NLM）

Optimizing Treatment for Early Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an autoimmune disease causing chronic joint inflammation. This study investigated the effectiveness of different treatment strategies for [early rheumatoid arthritis (ERA)], comparing [methotrexate (MTX)] with or without [glucocorticoid (GC)] remission induction to other intensive treatment regimens.

Tailoring Treatment to Individual Needs in Early Rheumatoid Arthritis

The study found that combining MTX with GCs was an effective treatment strategy for ERA, but the optimal schedule and feasibility in daily practice were debated. The results suggest that MTX with or without GC remission induction might be effective for patients with good prognosis, while other intensive strategies might be more appropriate for patients with poor prognosis.

Improving Outcomes for Rheumatoid Arthritis Patients

This research highlights the importance of tailoring treatment strategies for ERA based on individual patient characteristics and disease severity. The findings can inform clinical practice, guiding treatment decisions for patients with ERA and potentially leading to improved outcomes.

Dr.Camel's Conclusion

Imagine a desert oasis where different travelers seek refuge. Some travelers might need a simple well for water, while others might require a grand palace for shelter. Similarly, RA patients have diverse needs, and this study explores different treatment options to find the right fit for each individual. By understanding these unique needs, we can improve the lives of RA patients and ensure they find the best path to recovery.

Date :
  1. Date Completed 2017-06-13
  2. Date Revised 2022-03-10
Further Info :

Pubmed ID

27432356

DOI: Digital Object Identifier

10.1136/annrheumdis-2016-209212

Related Literature

Article Analysis
・Effective treatment of rheumatoid arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.